Literature DB >> 648214

Pharmacokinetics of theophylline in hepatic disease.

A Mangione, T E Imhoff, R V Lee, L Y Shum, W J Jusko.   

Abstract

The disposition of theophylline was examined in eight male cirrhotic (six proven by biopsy) patients without heart failure. An oral dose of 100 mg of theophylline per square meter of surface area was administered, and samples of serum and saliva were collected from 0 to 60 hours and were assayed by high-pressure liquid chromatographic techniques. Controls were 57 young normal subjects and 25 age-matched patients. The body clearance of theophylline in cirrhotic patients was low, averaging 18.8 +/- 11.3 ml/kg/hr (+/- SD) vs 53.7 +/- 19.3 and 63.0 +/- 28.5 ml/kg/hr in the control patients and the normal subjects, respectively. The half-life of theophylline in cirrhotic patients was prolonged wiht a mean of 28.8 +/- 14.3 hours compared to 6.0 +/- 2.1 hours in normal subjects. Patients with cirrhosis proven by biopsy had significantly lower values for body clearance and longer half-lives than subjects without biopsies. The values for body clearance correlated well with the serum level of bilirubin (r = -0.81) and the serum level of bile acids (r = -0.81). The slow and variable metabolism in cirrhotic patients necessitates a reduction in the maintenance dosage of aminophylline to 0.20 to 0.45 mg/kg/hr and monitoring of the serum level during therapy.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 648214     DOI: 10.1378/chest.73.5.616

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  32 in total

1.  Lack of effect of repirinast on the pharmacokinetics of theophylline in asthmatic patients.

Authors:  K Takagi; T Kuzuya; T Horiuchi; M Nadai; R Apichartpichean; Y Ogura; T Hasegawa
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 2.  Guide to drug dosage in hepatic disease.

Authors:  N M Bass; R L Williams
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

3.  Advocating for patients through clinical research.

Authors:  Leslie Hendeles
Journal:  J Pediatr Pharmacol Ther       Date:  2008-01

Review 4.  Influence of endogenous and exogenous effectors on the pharmacokinetics of theophylline. Focus on biotransformation.

Authors:  U Tröger; F P Meyer
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

5.  Impaired elimination of caffeine in cirrhosis.

Authors:  P V Desmond; R V Patwardhan; R F Johnson; S Schenker
Journal:  Dig Dis Sci       Date:  1980-03       Impact factor: 3.199

Review 6.  A clinical and pharmacokinetic basis for the selection and use of slow release theophylline products.

Authors:  L Hendeles; R P Iafrate; M Weinberger
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

Review 7.  Theophylline poisoning. Pharmacological considerations and clinical management.

Authors:  P Gaudreault; J Guay
Journal:  Med Toxicol       Date:  1986 May-Jun

8.  Theophylline elimination in congestive heart failure.

Authors:  H D Kuntz; H Straub; B May
Journal:  Klin Wochenschr       Date:  1983-11-02

Review 9.  Pharmacokinetic drug interactions with theophylline.

Authors:  J H Jonkman; R A Upton
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

10.  Theophylline and ethylenediamine pharmacokinetics following administration of aminophylline to septic patients with multiorgan failure.

Authors:  P Toft; L Heslet; M Hansen; N A Klitgaard
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.